In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case
Pfizer has discontinued its once-daily obesity pill danuglipron after a patient in one of its clinical trials had a liver injury that may have been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
